<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33621843</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Persistent SARS-2 infections contribute to long COVID-19.</ArticleTitle><Pagination><StartPage>110538</StartPage><MedlinePgn>110538</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2021.110538</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(21)00056-6</ELocationID><Abstract><AbstractText>COVID-19 is a serious disease that has infected more than 40 million people. Beside significant mortality, the SARS-CoV-2 infection causes considerable and sustained morbidity, dubbed long COVID. This paper argues that some of this morbidity may be due to a persistent systemic infection. Persistent infection is indicated by continued virus RNA shedding. The virus' superantigen could overstimulate anti-virus immune responses, and thereby induce negative feedback loops, that paradoxically allow the virus to persist. The superantigen would induce strong immune response to any residual infection. This hypothesis suggests that clearing the virus infection completely would be an appropriate intervention against long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>John J L</ForeName><Initials>JJL</Initials><AffiliationInfo><Affiliation>ORTEC BV, Dept. of Health, Houtsingel 5, Zoetermeer 2719 EA, the Netherlands. Electronic address: John.Jacobs@ortec.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018089">Superantigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018089" MajorTopicYN="N">Superantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="Y">Virus Shedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33621843</ArticleId><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2021.110538</ArticleId><ArticleId IdType="pii">S0306-9877(21)00056-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P., Yang X.-L., Wang X.-G., et al.  A pneumonia outbreak associated with a new coronavirus of probably bat origin. Nature. 2020;579:270&#x2013;273. doi: 10.1038/s41586-020-2012-7.  https://www.nature.com/articles/s41586-020-2012-7.pdf CrossRefView.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymus COVID-19 coronavirus pandemic. Assessed 18-10-2020. https://www.worldometers.info/coronavirus/ CrossRefView N.A.</Citation></Reference><Reference><Citation>Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates medRxiv (2020) preprint https://www.medrxiv.org/content/10.1101/2020.05.03.20089854v4.full.pdf CrossRefView. https://doi.org/10.1101/2020.05.03.20089854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.03.20089854v4.full.pdf</ArticleId><ArticleId IdType="pmc">PMC7524446</ArticleId><ArticleId IdType="pubmed">33007452</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 324; 2020: 603&#x2013;605. https://jamanetwork.com/journals/jama/fullarticle/2768351 CrossRefView. https://doi.org/10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: what do we know about &#x201c;long covid&#x201d;? BMJ 370; 2020: m2815. https://www.bmj.com/content/370/bmj.m2815 CrossRefView. http://dx.doi.org/10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMG, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020 [in press]. https://openres.ersjournals.com/content/erjor/early/2020/09/01/23120541.00542-2020.full.pdf CrossRefView. https://doi.org/10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Kapur S, et al. Multi-organ impairment in low-risk individuals with long COVID Submitted https://www.medrxiv.org/content/10.1101/2020.10.14.20212555v1.full.pdf CrossRefView. https://doi.org/10.1101/2020.10.14.20212555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212555v1.full.pdf</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long covid: how to define it and how to manage it. BMJ 370; 2020: m3489. https://www.bmj.com/content/bmj/370/bmj.m3489.full.pdf CrossRefView. http://dx.doi.org/10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Am J Emerg Med 38; 2020: 1549.e3&#x2013;1549.e7. https://linkinghub.elsevier.com/retrieve/pii/S0735675720303648 CrossRefView. https://doi.org/10.1016\j.ajem.2020.05.024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229718</ArticleId><ArticleId IdType="pubmed">32425321</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta A, Kalhan A, Kalra S.. Long term complications and rehabilitation of COVID-19 patients. J Pak Med Assoc 70; 2020: S131&#x2013;S13. https://www.ejmanager.com/mnstemps/33/33-1589041918.pdf?t=1601748998 CrossRefView. https://doi.org/10.5455/JPMA.32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32515393</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung T, Chan A, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect 17; 2020: 1&#x2013;19. https://doi.org/10.1080/22221751.2020.1825914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586446</ArticleId><ArticleId IdType="pubmed">32940572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongio&#xec; LM, Barbagallo F, Condorelli RA, et al. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine 68; 2020: 467&#x2013;470. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266418/pdf/12020_2020_Article_2349.pdf CrossRefView. https://doi.org/10.1007/s12020-020-02349-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266418</ArticleId><ArticleId IdType="pubmed">32488837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. New Sci 246; 2020: 10&#x2013;11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194715/pdf/main.pdf CrossRefView. https://dx.doi.org/10.1016%2FS0262-4079(20)30746-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194715</ArticleId><ArticleId IdType="pubmed">32372811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister BA. Post-infectious disease syndrome. Postgrad Med J 64; 1988: 559&#x2013;567. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2428896/pdf/postmedj00187-0079.pdf CrossRefView. https://dx.doi.org/10.1136%2Fpgmj.64.753.559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2428896</ArticleId><ArticleId IdType="pubmed">3074289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho-Yen DO. The epidemiology of post viral fatigue syndrome scott. Med J 33; 1988: 368&#x2013;9. https://journals.sagepub.com/doi/10.1177/003693308803300607?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed CrossRefView. https://doi.org/10.1177%2F003693308803300607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003693308803300607%3furl_ver%3dZ39.88-2003%26rfr_id%3dori%3arid%3acrossref.org%26rfr_dat%3dcr_pub%2520%25200pubmed</ArticleId><ArticleId IdType="pubmed">2854300</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 4; 2020: 1&#x2013;2. https://www.nature.com/articles/s41584-020-0448-7 CrossRefView. https://dx.doi.org/10.1038%2Fs41584-020-0448-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun 16; 2020: 102506. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296326/pdf/main.pdf CrossRefView. https://dx.doi.org/10.1016%2Fj.jaut.2020.102506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296326</ArticleId><ArticleId IdType="pubmed">32563547</ArticleId></ArticleIdList></Reference><Reference><Citation>Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Macario AJL, Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 19; 2020: 102591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289093/pdf/main.pdf CrossRefView. https://dx.doi.org/10.1016%2Fj.autrev.2020.102591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289093</ArticleId><ArticleId IdType="pubmed">32535095</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, Uhal BD. COVID-19-A theory of autoimmunity to ACE-2. MOJ Immunol 7; 2020: 17&#x2013;19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351250/pdf/nihms-1601975.pdf CrossRefView. https://doi.org/10.15406/moji.2020.07.00257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351250</ArticleId><ArticleId IdType="pubmed">32656314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL, Leh&#xeb; CL, Hasegawa H, Elliott GR, Das PK. Skin irritants and contact sensitizers induce Langerhans cell migration and maturation at irritant concentration. Exp Dermatol 15; 2006: 432&#x2013;40. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.0906-6705.2006.00420.x CrossRefView. https://doi.org/10.1111/j.0906-6705.2006.00420.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0906-6705.2006.00420.x</ArticleId><ArticleId IdType="pubmed">16689859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousseff M, Penot P, Gallay L, et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect 2020: S0163-4453(20)30454-0. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326402/pdf/main.pdf. https://doi.org/10.1016/j.jinf.2020.06.073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326402</ArticleId><ArticleId IdType="pubmed">32619697</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Nat Acad Sci 2020 [in press]. https://www.pnas.org/content/pnas/early/2020/09/25/2010722117.full.pdf CrossRefView https://doi.org/10.1073/pnas.2010722117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Luo C, Li W. Immunity and virulence of SARS coronavirus. Viral Immunol 17; 2004: 528&#x2013;34. https://www.liebertpub.com/doi/10.1089/vim.2004.17.528?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed CrossRefView. https://doi.org/10.1089/vim.2004.17.528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2004.17.528%3furl_ver%3dZ39.88-2003%26rfr_id%3dori%3arid%3acrossref.org%26rfr_dat%3dcr_pub%2520%25200pubmed</ArticleId><ArticleId IdType="pubmed">15671749</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglioni V, Soriano ER. Are superantigens the cause of cytokine storm and viral sepsis in severe COVID-19? Observations and hypothesis Scand J Immunol 2020: e12944. https://doi.org/10.1111/sji.12944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404497</ArticleId><ArticleId IdType="pubmed">32697367</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci 256; 2020: 117900. https://reader.elsevier.com/reader/sd/pii/S0024320520306500?token=56891288C7D70B0EB0692A90F3A030F47FA11015D1CC6FE05CCEEB33233DE6063C2D0BC4DFD76B7A43DD5EB033F82DC9 CrossRefView. https://dx.doi.org/10.1016%2Fj.lfs.2020.117900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266583</ArticleId><ArticleId IdType="pubmed">32502542</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoletti M, Marconi L, Scudeller L, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect 2020: S1198-743X(20)30563-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506332/pdf/main.pdf CrossRefView. https://doi.org/10.1016/j.cmi.2020.09.014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7506332</ArticleId><ArticleId IdType="pubmed">32971254</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber BT, Hsu P-N, Sutkowski N. Virus-encoded superantigens. Microbiol Rev 60; 1996: 473&#x2013;482. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC239452/pdf/600473.pdf CrossRefView N.A.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC239452</ArticleId><ArticleId IdType="pubmed">8840782</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Op Virol 23; 2017: 35&#x2013;42. https://www.sciencedirect.com/science/article/pii/S1879625716301559?via%3Dihub CrossRefView. https://doi.org/10.1016/j.coviro.2017.03.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5474179</ArticleId><ArticleId IdType="pubmed">28319790</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Diao B, Wang R, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv 2020. Preprint. https://www.medrxiv.org/content/10.1101/2020.03.27.20045427v1.full.pdf CrossRefView. https://doi.org/10.1101/2020.03.27.20045427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.27.20045427v1.full.pdf</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL. Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 143; 2020: 109884. https://www.sciencedirect.com/science/article/pii/S0306987720311270 CrossRefView. https://doi.org/10.1016/j.mehy.2020.109884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832094</ArticleId><ArticleId IdType="pubmed">32512289</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y-H, Ni W, Wu Q, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect 53; 2020: 473&#x2013;480. https://www.sciencedirect.com/science/article/pii/S1684118220300815?via%3Dihub CrossRefView. https://doi.org/10.1016/j.jmii.2020.03.021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141453</ArticleId><ArticleId IdType="pubmed">32276848</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Venkatakrishnan AJ, Puranik A, et al. Quantifying the prevalence of SARS-CoV-2 long-term shedding among non-hospitalized COVID-19 patients. medRxiv 2020: 2020.06.02.20120774 (preprint). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302207/pdf/nihpp-2020.06.02.20120774.pdf CrossRefView. https://doi.org/10.1101/2020.06.02.20120774.</Citation></Reference><Reference><Citation>Sethuraman M, Stanleyraj Jeremiah S, Ryo A. Interpreting diagnostic tests for SARS-CoV-2 JAMA.323 2020: 2249&#x2013;2251. https://jamanetwork.com/journals/jama/fullarticle/2765837 CrossRefView. https://doi.org/10.1001/jama.2020.8259.</Citation><ArticleIdList><ArticleId IdType="pubmed">32374370</ArticleId></ArticleIdList></Reference><Reference><Citation>Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health 25; 2020: 210&#x2013;215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237903/pdf/main.pdf CrossRefView. https://doi.org/10.1016/j.idh.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237903</ArticleId><ArticleId IdType="pubmed">32473952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkeri R., Goebel S., Sharma G.D. SARS-CoV-2 shedding from asymptomatic patients: contribution of potential extrapulmonary tissue reservoirs. Am J Trop Med Hyg. 2020;103:18&#x2013;21. doi: 10.4269/ajtmh.20-0279.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-0279</ArticleId><ArticleId IdType="pmc">PMC7356473</ArticleId><ArticleId IdType="pubmed">32406369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang VT, Dao TL, Gautret P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. J Med Virol 2020. 10.1002/jmv.26056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280660</ArticleId><ArticleId IdType="pubmed">32449789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann CC, Lane TE, Stohlman SA. Coronavirus infection of the central nervous system: host&#x2013;virus stand-off. Nat Rev Microbiol 4; 2006: 121&#x2013;132. https://www.nature.com/articles/nrmicro1343 CrossRefView. https://doi.org/10.1038/nrmicro1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096820</ArticleId><ArticleId IdType="pubmed">16415928</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner D, Marro BS, Lane TE. Chemokine CXCL10 and coronavirus-induced neurologic disease. Viral Immunol 32; 2019: 25&#x2013;37. https://doi.org/10.1089/vim.2018.0073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350065</ArticleId><ArticleId IdType="pubmed">30109979</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler Christian, Wang Zijun, Lorenzi Julio, et al.  Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 https://pubmed.ncbi.nlm.nih.gov/33461210/ In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne S, Thibodeau L, Lamontagne L. Clonal deletion of some V beta+ T cells in peripheral lymphocytes from C57BL/6 mice infected with MHV3. In: Enjuanes L., Siddell S.G., Spaan W. (eds) Coronaviruses and Arteriviruses. Advances in Experimental Medicine and Biology, vol. 440. Springer: Boston, MA; 1998. pp. 485-489. https://doi.org/10.1007/978-1-4615-5331-1_62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9782319</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Wang L, Kong X, et al. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients. J Med Virol 92; 2020: 1684&#x2013;1689. https://doi.org/10.1002/jmv.25946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267623</ArticleId><ArticleId IdType="pubmed">32343415</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Nou&#xeb;n C, Hillyer P, Munir S, et al. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 5; 2010: e15017. https://doi.org/10.1371/journal.pone.0015017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993941</ArticleId><ArticleId IdType="pubmed">21124776</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med 2020 [in press]. https://doi.org/10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafaie L, C&#xe9;larier T, Goethals L, et al. Recurrence or relapse of COVID-19 in older patients: a description of three cases. J Am Geriatr Soc 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361461/pdf/JGS-9999-na.pdf CrossRefView https://dx.doi.org/10.1111%2Fjgs.16728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361461</ArticleId><ArticleId IdType="pubmed">32638347</ArticleId></ArticleIdList></Reference><Reference><Citation>Shastri J, Parikh S, Agrawal S, et al. Whole genome sequencing confirmed SARS-CoV-2 reinfections among healthcare workers in india with increased severity in the second episode. The Lancet 2020. preprint. https://papers.ssrn.com/sol3/Delivery.cfm/17b5cdc9-d7f9-4c47-8700-abfaec970b2e-MECA.pdf?abstractid=3688220&amp;mirid=1 CrossRefView. https://dx.doi.org/10.2139/ssrn.3688220.</Citation></Reference><Reference><Citation>Vu BG, Stach CS, Kulhaankova K, Salgado-Pab&#xf3;n W, Klingelhutz AJ, Schlievert PM. Chronic superantigen exposure induces systemic inflammation, elevated bloodstream endotoxin, and abnormal glucose tolerance in rabbits: possible role in diabetes. mBio 6; 2015: e02554-14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358007/pdf/mBio.02554-14.pdf CrossRefView. https://doi.org/10.1128/mBio.02554-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358007</ArticleId><ArticleId IdType="pubmed">25714716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghisolfi S, Alm&#xe5;s I, Sandefur JC, Von Carnap T, Heitner J, Bold T. Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity. BMJ Global Health 5; 2020: e003094. https://gh.bmj.com/content/bmjgh/5/9/e003094.full.pdf CrossRefView. http://dx.doi.org/10.1136/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482102</ArticleId><ArticleId IdType="pubmed">32912856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun Rev 19; 2020: 102567. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196557/pdf/main.pdf CrossRefView. https://doi.org/10.1016/j.autrev.2020.102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomova R, Antonov K, Ivanova A, et al. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report. Anticancer Res 12; 2009: 5241&#x2013;4. http://ar.iiarjournals.org/content/29/12/5241.full.pdf+html CrossRefView N.A.</Citation><ArticleIdList><ArticleId IdType="pubmed">20044643</ArticleId></ArticleIdList></Reference><Reference><Citation>Characiejus D, Pasukoniene V, Kazlauskaite N, et al. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22; 2002: 3679&#x2013;83. https://pubmed.ncbi.nlm.nih.gov/12552976/ CrossRefView N.A.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552976</ArticleId></ArticleIdList></Reference><Reference><Citation>Characiejus D., Hodzic J., Jacobs J.J.L. &#x201c;First do no harm&#x201d; and the importance of prediction in oncology. EPMA J. 2010;1:369&#x2013;375. doi: 10.1007/s13167-010-0042-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-010-0042-1</ArticleId><ArticleId IdType="pmc">PMC2987560</ArticleId><ArticleId IdType="pubmed">21151487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>